Views & Analysis Exclusive: Brexit likely to cause long-term damage to UK pha... Exclusive survey finds concerns about future of UK pharma industry
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.